| (R/S)-Alicaforsen |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.27% |
| (S)-Deethyl-emvistegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (S,R)-Emvistegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12(S)-HETrE |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| 13-Hydroxylupanine |
|
|
|
|
|
|
|
|
|
|
|
|
|
97% |
| 2-Methylbutyrylcarnitine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| 264RAD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3-Hydroxyxanthone |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| 3P-RGD2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 6-B345TTQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A-205804 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| A-286982 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.12% |
| A20FMDV2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| A20FMDV2-Cys |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AB-3PRGD2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ABH hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Ac-MRGDH-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-RGDS-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adxanthromycin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AFP464 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AFP464 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| AFP464 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alicaforsen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alicaforsen sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alicaforsen sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alkyne-cRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| Anti-CD103 Antibody (hCD103.01A) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD11a Antibody (MHM24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD11a/LFA-1α Antibody (R7-1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD11b Antibody (ICRF44) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD11c Antibody (3.9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD54/ICAM-1 Antibody (R6-5-D6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-DC-SIGN/CD209 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Anti-EMMPRIN/CD147 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Anti-Fibronectin III Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Fibulin-4 Antibody (5G11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-ICAM3/CD50 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Integrin α5β1 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Integrin α9 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Integrin αvβ8 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-ITGAD Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-ITGB1 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
96.16% |
| Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse CD103 Antibody (M290) |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| Anti-Mouse CD11a Antibody (FD441.8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse CD11a Antibody (I21/7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD11a/LFA-1α Antibody (M17/4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse CD11b Antibody (5C6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD18 Antibody (C71/16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD18 Antibody (M18/2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
| Anti-Mouse CD29 Antibody (KMI6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| Anti-Mouse CD41 Antibody (S-R690) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CD54 Antibody (YN1/1.7.4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse ICAM-1 Antibody (BE29G1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Anti-Mouse MAdCAM-1 Antibody (MECA-89) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse/Human CD11b Antibody (M1/70) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse/Human Integrin β7 Antibody (FIB504) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Anti-NRP2 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Rat CD11b/c Antibody (OX42) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-vWF Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
97.89% |
| Arg-Gly-Asp TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arg-Gly-Asp-Ser |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| Arg-Gly-Asp-Ser TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arg-Gly-Glu-Ser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arg-Gly-Glu-Ser TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| ASD141 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASP5094 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATL 1102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATL 1102 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATL 1102 sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATN-161 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| ATN-161 trifluoroacetate salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| ATTO 740 NHS ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Azide-iRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| Batifiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bersanlimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Bexotegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Bexotegrast hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BGC0222 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BI-1950 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIO-1211 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| BIO5192 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| BIO5192 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIO5192 hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| BIO7662 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BIRT 377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| BIRT2584 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMS-587101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.39% |
| BMS-688521 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| BOP sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| BT100 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BTT-3033 |
|
|
|
|
|
|
|
|
|
|
|
|
|
96.57% |
| BTT-3034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c(avb6)-DOTA TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| c(phg-isoDGR-(NMe)k) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c(phg-isoDGR-(NMe)k) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| c-RGD-SH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c-RGD-SH TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| C16Y |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C16Y acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.60% |
| Carotegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| Carotegrast methyl |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Carotegrast methyl hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Certepetide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Certepetide-13C2,15N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Certepetide-13C6,15N2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chrysotobibenzyl |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cilengitide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| CLT-28643 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CP-664511 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| cRGDfK-thioacetyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| cRGDfK-thioacetyl ester TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Crocatin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CWHM-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Cyclic αvβ6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyclo(-RGDfK) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Cyclo(-RGDfK) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| Cyclo(Ala-Arg-Gly-Asp-Mamb) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Cyclo(Arg-Gly-Asp-D-Phe-Cys) |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| Cyclo(Arg-Gly-Asp-D-Phe-Val) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| Cyclo(GRGDSPA) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyclo(phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cyclo(RADfK) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Cyclo(RGDyK) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Cyclo(RGDyK) trifluoroacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Cyclopeptide-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cys-αvβ6-BP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cys-αvβ6-BP TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D-RGDW |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deethyl-emvistegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deethyl-emvistegrast TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dentonin TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Des-ethyl-carafiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| diABZI-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.33% |
| Dihydropelitinib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DOTA-ADIBO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| DSPE-PEG1000-cRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DSPE-PEG1000-iRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DSPE-PEG2000-cRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DSPE-PEG2000-iRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| DSPE-PEG3000-iRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DSPE-PEG3400-cRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DSPE-PEG3400-iRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DSPE-PEG5000-cRGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| E(c(RGDfK))2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| E7820 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Echistatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
91.33% |
| Echistatin TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| Egaptivon pegol |
|
|
|
|
|
|
|
|
|
|
|
|
|
90.03% |
| Egaptivon pegol sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
92.75% |
| Egaptivon pegol sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EILEVPST |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
| Elarofiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elarofiban diTFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elsibucol |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| EMD-132338 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EMD527040 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| EMD527040 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Emvistegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.06% |
| Emvistegrast axial isomer |
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| Endothelin-3, human, mouse, rabbit, rat |
|
|
|
|
|
|
|
|
|
|
|
|
|
97.58% |
| Endothelin-3, human, mouse, rabbit, rat TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Eptifibatide acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Euchrestaflavanone A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Excisanin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fibrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fibrinogen Binding Inhibitor Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Fibrinogen γ-chain (117-133) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Fibrinogen-Binding Peptide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| Fibronectin active fragment control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fibronectin CS1 Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Fibronectin sctive fragment control acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Fibronectin Type III Connecting Segment Fragment 1-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| FK 633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FNIII14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FR-158999 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fradafiban hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| FSC(PEG4-αvβ6)₃ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Furtisetabart |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Fuzapladib |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.75% |
| Fuzapladib calcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fuzapladib potassium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fuzapladib sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| FZ1 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| G-Pen-GRGDSPCA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| G-Pen-GRGDSPCA TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| G-{d-Arg}-GDSP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| G4RGDSP, integrin-binding peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Galacto-RGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganglioside GM2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Ganodermaones B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gantofiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GFOGER peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| GLPG0187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Gly-Arg-Gly-Asp-Ser |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Gly-Arg-Gly-Asp-Ser TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GP1 precursor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPRP acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| GR144053 trihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GR83895 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GREDVGC |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| GRGDSP |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| GRGDSP TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| GRGDSPK |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| GRGDSPK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grp94-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK 3008348 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| GSK 3008348 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| GSK3335103 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GW559090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| H-Gly-Pro-Arg-Pro-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HB-3-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HMR 1031 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HSDVHK-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| HSDVHK-NH2 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| huATN-658 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Hydrostatin-TL1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydroxyflutamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| HYNIC-3P-RGD2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ICAM-1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| ICAM-1988 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDR 1002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| ILK-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| IMB-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IMGN388 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Integrin antagonist 27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Integrin Binding Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Integrin modulator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Integrin signaling inhibitor, mP13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Integrin-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.23% |
| IPS-05002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| iRGD peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| iRGD-CPT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Irigenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| ITGB3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| IVL 745 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JNJ-26076713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| K34c |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| K34c hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| KAFDITYVRLKF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KBU2046 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| KGDS |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| L-703014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-734217 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-738167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-739758 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-767685 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L123Z358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lamifiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lamifiban TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LDV |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| LDV-FITC |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| LDV-FITC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lefradafiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Leukadherin-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Levocabastine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Levocabastine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| LFA-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lotrafiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lotrafiban hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LT25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.73% |
| LVTX-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LXW7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| LXW7 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| LXY3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.33% |
| Lys-Gln-Ala-Gly-Asp-Val |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| Maleimide-NOTA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Maltotetraose |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Maraciclatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ME-3277 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milategrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| MINT1526A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-0429 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| MK-0668 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-0668 mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MK-852 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ML165 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MLN2201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MNS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MOR101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MOR102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MORF-627 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MorHap |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| mP6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| mP6 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| MSH-TP15e |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mumefural |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.17% |
| myr-RGT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyl-S-geranylgeranyl-L-cysteine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NAMI-A |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Natalizumab (Anti-CD49d) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Necrosulfonamide-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Nesvategrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nexinhib20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| NM-001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOTA-Asp2-αvβ6L |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOTA-IMB-RGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NPC-15669 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NYLTHRQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Obtustatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Obtustatin triacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Orbofiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Orbofiban acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| OS-2966 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| OSU-T315 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| PAS-003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDI-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PLN-1474 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Pyrintegrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Q-Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| R-BC154 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RBN012811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| REDV |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| REDV TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Relitegatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RGD |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| RGD Negative Control |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| RGD peptide (GRGDNP) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| RGD peptide (GRGDNP) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| RGD Trifluoroacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| RGD-4C |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| RGD-DA6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RGDSPASSKP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risuteganib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risuteganib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| Ro 43-5054 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RO0270608 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Rondaptivon pegol |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| Rondaptivon pegol sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
93.15% |
| Rondaptivon pegol sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Roxifiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RPR-109891 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RTDLDSLRTYTL |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RTDLDSLRTYTL TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RUC-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RWJ 50271 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| SAN-300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SB-267268 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| SB-273005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| SC-52012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SC-68448 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SD3A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sibrafiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Sigvotatug |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Sigvotatug (Biotinylated) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sigvotatug vedotin |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| SM6.1-azide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SP-8008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SPP-037 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SR121566A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ST6GAL1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| STX-100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| SU015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sulfobacin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Surfactin C1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Synstatin (92-119) |
|
|
|
|
|
|
|
|
|
|
|
|
|
97.61% |
| T7 Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| T7 Peptide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.20% |
| TAK-029 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBC-4746 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBC3486 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TC-I 15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| TC-I 15 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TC113 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TCS 2314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.5% |
| TG53 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| THR-123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| THR-123 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TR-14035 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| TRAP-14 amide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tri-SM6.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tris-ανβ6 integrin ligand-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tris-ανβ6 integrin ligand-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tris-ανβ6 integrin ligand-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UR-12947 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UR-2922 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UR-3216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Valategrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Valategrast hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Variabilin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vedolizumab (anti-α4β7-integrin) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Ventegatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VIP236 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitronectin (367-378) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| VnP-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VPI-2690B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VSLRGDTRG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VSLRGDTRG acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Xemilofiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| XV459 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| XVA143 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| YRGDS Fibronectin Fragment |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.46% |
| Zalunfiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zalunfiban acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zalunfiban dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Zaurategrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| Zaurategrast ethyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| Zaurategrast ethyl ester sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZD 2486 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α2β1 Integrin Ligand Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| α2β1 Integrin Ligand Peptide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| α4 integrin receptor antagonist 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α4β1 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α4β7 Integrin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α4β7 Integrin-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α5β1 integrin agonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| α5β1 integrin agonist-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| α5β1 integrin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α7β1 integrin modulator-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| αLβ2 integrin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αMβ2 integrin agonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ1 integrin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| αvβ1 integrin-IN-1 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.28% |
| αvβ1 integrin-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ1 integrin-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ5 integrin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| αvβ6 integrin inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ6-BP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ6-BP TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αvβ6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| αVβ8-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
96.31% |
| ανβ6 Integrin ligand-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ανβ6 Integrin ligand-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Levocarnitine propionate hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Tadocizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
97% |
| Volociximab |
|
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Vatelizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Etrolizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| Efalizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Pinatuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Caplacizumab (His Tag) |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Erlizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| Eptifibatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Eptifibatide monoacetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Etaracizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Fradafiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STX-100 (Biotinylated) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoxanthohumol |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Isoastragaloside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Cardenolide B-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Enlimomab |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Ontamalimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Tirofiban |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Tirofiban-d9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collagen (bovine skin) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phellopterin |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Tetrac |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| Tirofiban hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tirofiban hydrochloride monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Lifitegrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Lifitegrast-d4-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lifitegrast sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Fibronectin |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.7% |
| Vedolizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Veltuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| PA-IIL |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rovelizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
97.23% |
| Polyether F127 Diacrylate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Suciraslimab |
|
|
|
|
|
|
|
|
|
|
|
|
|
97.42% |
| Intetumumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Cucurbitacin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Spirulina C-phycocyanin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cilengitide |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Natalizumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Roxifiban acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recombinant Humanized Type III Collagen 28.6kDa |
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Recombinant humanized type III collagen (MW 55900) |
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Abrilumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
98.35% |
| Abciximab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Abituzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Firategrast |
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |